In conclusion, treatment with canagliflozin in addition to teneligliptin decreases urinary albumin excretion, at least in part, through the reduction of blood pressure and improves a variety of metabolic parameters in a glucagon-independent manner in Japanese subjects with type 2 diabetes mellitus. Here, ALB is linked to type 2 diabetes mellitus.